Oncology

Zolbetuximab is the first approved CLDN18.2-targeted treatment for gastric and gastroesophageal junction adenocarcinoma.

The tool can detect cell changes and mutations that drive resistance and relapse.

Awareness of uterine fibroids and uterine fibroid embolization can prevent unnecessary hysterectomies, especially in Black women, who are more likely to have uterine fibroids.

This review discusses the significance of the FDA-approved drug inotuzumab ozogamicin in pediatric patients with acute lymphocytic leukemia (ALL) and relapsed/refractory (R/R) ALL, and the evolving therapeutic options in R/R ALL.

Compared with brentuximab vedotin and chemotherapy, nivolumab and chemotherapy had longer progression-free survival and a better safety profile.

This retrospective cohort study provides preliminary evidence for safe removal of mesna from VAdriaC cycles, as the incidence of hemorrhagic cystitis did not increase in patients with Ewing sarcoma who received cyclophosphamide without prophylactic mesna.

HER2-mutant NSCLC is associated with poor prognosis. Zongertinib and BAY 2927088 are HER2 tyrosine kinase inhibitors that have activity in NSCLC with manageable toxicity profiles.

The KEYNOTE-756 and CheckMate 7FL trials show this combination improves pathological complete response rates in this patient population.

The results indicate the potential use of loncastuximab tesirine as a treatment option for the rare hyperinflammatory condition.

Artificial intelligence holds immense potential to address the rising demand for oncology services and improve patient outcomes by facilitating more effective, efficient, personalized cancer care.

The drug's safety profile included significant rates of nausea, vomiting, and hematologic toxicities like neutropenia and thrombocytopenia. Although promising, brigimadlin requires careful management of adverse effects, including antiemetic and hematologic support.

Although respondents identified some exciting areas of growth, challenges remain, including the complex insurance system and ensuring patient medication adherence.

Behind The Script is a photo submission campaign designed to feature real pharmacists with candid, HIPAA-compliant photos to celebrate American Pharmacist Month.

The authors of these peer -reviewed papers collectively emphasize the evolving landscape of oncology treatment.

The trial met its primary endpoint of event-free survival, furthering treatment options for resected, locally advanced head and neck squamous cell carcinoma.

A breast-level artificial intelligence score may be able to estimate the risk of future breast cancer, allowing for patients to take preventative measures.

The FDA also approved the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients who would benefit from the treatment.

The real-world study results of ciltacabtagene autoleucel are comparable to data from the CARTITUDE-1 trial, emphasizing its efficacy and safety.

The addition of high-dose vitamin D3 to standard treatment did not delay the progression of cancer compared with the standard dose of vitamin D3.

Victor Ambros and Gary Ruvkun received the 2024 Nobel Prize in Physiology or Medicine for discovering microRNA and its role in gene regulation.

Treosulfan showed superior benefits to busulfan as a conditioning regimen before allogenic hematopoietic stem cell transplantation (allo-HSCT).

Patients in persistently impoverished areas were also more likely to have more aggressive tumor characteristics and receive more invasive surgeries.

The results show promise for the use of Bruton tyrosine kinase inhibitors in non-Hodgkin lymphoma treatment.

Nivolumab is the only PD-1 inhibitor to show statistically significant and clinically meaningful benefits in non-small cell lung cancer compared with chemotherapy.

The new screening test provides an easier, convenient option for patients seeking to screen themselves for colorectal cancer.

Currently, standard first-line chemotherapy with or without immunotherapy for patients with non-small-cell lung cancer (NSCLC) with HER2 mutations has limited efficacy.

Fedratinib is an orally available, small molecule inhibitor of JAK-2 approved for treatment of myelofibrosis.

Eculizumab (Soliris; Alexion), a C5 inhibitor preventing cleavage into C5a and C5b, is widely considered the first-line therapy for high-risk TA-TMA.

Currently, VLS-1488 is being evaluated in a phase 1/2 trial (NCT05902988) in various advanced tumors, including high-grade serous ovarian cancer (HGSOC).